Trial NCT04611776

View at ClinicalTrials.gov 
Org. Study IDs: YO41867

Last trial update was posted on 2021-06-16

MeSH Interventions

Atezolizumab Carboplatin Gemcitabine Paclitaxel Pemetrexed

MeSH Conditions

Carcinoma, Non-Small-Cell Lung

Other Conditions

Carcinoma, Non-Small Cell Lung

Stopping Reasons

The positive results from IMpower010 demonstrated benefit by adding atezolizumab as adjuvant therapy in early stage NSCLC. These results raised ethical concerns of enrolling pts to best supportive care over checkpoint inhibition in this setting.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID